Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Return on Equity (2017 - 2025)

Historic Return on Equity for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to 1.15%.

  • Aclaris Therapeutics' Return on Equity fell 8600.0% to 1.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.15%, marking a year-over-year decrease of 8600.0%. This contributed to the annual value of 0.84% for FY2024, which is 3500.0% down from last year.
  • As of Q3 2025, Aclaris Therapeutics' Return on Equity stood at 1.15%, which was down 8600.0% from 1.0% recorded in Q2 2025.
  • Aclaris Therapeutics' 5-year Return on Equity high stood at 0.27% for Q2 2021, and its period low was 1.15% during Q3 2025.
  • In the last 5 years, Aclaris Therapeutics' Return on Equity had a median value of 0.43% in 2021 and averaged 0.56%.
  • Its Return on Equity has fluctuated over the past 5 years, first skyrocketed by 4200bps in 2024, then plummeted by -8600bps in 2025.
  • Over the past 5 years, Aclaris Therapeutics' Return on Equity (Quarter) stood at 0.43% in 2021, then rose by 1bps to 0.43% in 2022, then crashed by -38bps to 0.59% in 2023, then tumbled by -58bps to 0.94% in 2024, then fell by -23bps to 1.15% in 2025.
  • Its last three reported values are 1.15% in Q3 2025, 1.0% for Q2 2025, and 0.89% during Q1 2025.